期刊
BONE
卷 70, 期 -, 页码 87-92出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bone.2014.07.020
关键词
Bone marrow stromal cells; Good manufacturing practices; Cell factories; Bioreactor
资金
- Intramural Research Program of NIDCR
- Intramural Research Program of NCI
- Intramural Research Program of NHLBI
- Intramural Research Program of NIAID
- Intramural Research Program of NIAMS
- Intramural Research Program of NIBIB
- Intramural Research Program of NINDS
- Intramural Research Program of CC
- Intramural Research Program of the NIH DHHS [1ZIBDE000730]
- NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000380] Funding Source: NIH RePORTER
- CLINICAL CENTER [ZIACL002120] Funding Source: NIH RePORTER
In current orthopaedic practice, there is a need to increase the ability to reconstruct large segments of bone lost due to trauma, resection of tumors and skeletal deformities, or when normal regenerative processes have failed such as in non-unions and avascular necrosis. Bone marrow stromal cells (BMSCs, also known as bone marrow-derived mesenchymal stem cells), when used in conjunction with appropriate carriers, represent a means by which to achieve bone regeneration in such cases. While much has been done at the bench and in pre-clinical studies, moving towards clinical application requires the generation of clinical grade cells. What is described herein is an FDA-approved cell manufacturing procedure for the ex vivo expansion of high quality, biologically active human BMSCs. This article is part of a Special Issue entitled Stem Cells and Bone. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据